Clinical trials: L-Arginine
Gastroenteropancreatic Neuroendocrine Tumors
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post…
- Trial name
- NCT04524442
- Testing
- arginine/lysine
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 42 people
- Sponsor
- Advanced Accelerator Applications
Bioequivalence, Healthy Subjects
Bioequivalence Study of 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide / 10 mg Amlodipine Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide / 10 mg Amlodipine Film-Coated Tablets in Healthy Volunteers
The present study is a comparative bioavailability study performed to assess bioequivalence between a Test medication (PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets…
- Trial name
- NCT05470764
- Testing
- PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets, TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets
- Where
- Jordan
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Darnitsa Pharmaceutical Company
Nonalcoholic Steatohepatitis (NASH)
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
Evaluate efficacy and safety of ADI-PEG 20 in patients with NASH
- Trial name
- NCT05842512
- Testing
- ADI-PEG20
- Where
- 10 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- Polaris Group
Neoplasms, Solid Tumor, Adult
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
The purpose of the study is to identify the maximum tolerated dose (MTD) of JNJ-64619178 in participants with relapsed/refractory B cell non-Hodgkin lymphoma (NHL) or advanced solid tumors and also to identify the recommended…
- Conditions
- Neoplasms, Solid Tumor, Adult, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT03573310
- Testing
- JNJ-64619178
- Where
- 18 sites in United States, Canada and 3 more
- Volunteers
- 114 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Pancreatic Cancer
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.
- Trial name
- NCT02101580
- Testing
- ADI-PEG 20
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Polaris Group
Bioequivalence
Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions
This is an open-labeled, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Prestarium ® A 10 mg tablets) or the test (Perindopril 8 mg tablets)…
- Trial name
- NCT06213610
- Testing
- Perindopril tablet, Prestarium® A tablet
- Where
- Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pharmtechnology LLC
Sensitivity, Tooth
To Assess the Efficacy of a Toothpaste Containing 8% Arginine as Compared to Colgate Cavity Protection Toothpaste in the Reduction of Dentinal Hypersensitivity.
The objective of this clinical investigation is to assess the efficacy of a toothpaste containing 8% arginine (Colgate-Palmolive Company, New York, NY, USA) as compared to a commercially available non-desensitizing toothpaste…
- Trial name
- NCT07149376
- Testing
- TOMs of Maine Sensitive SLS Free Xtra Fresh, Colgate Cavity protection toothpaste
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Obesity & Overweight
Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment
This study evaluates whether a Food for Special Medical Purposes (FSMP) can help to preserve appendicular skeletal muscle mass (ASMM) in adults undergoing weight loss treatment with GLP-1 receptor agonists or dual GIP/GLP-1…
- Trial name
- MYO-PRESERVE (NCT07393360)
- Testing
- Myosave®
- Where
- 3 sites in Italy
- Volunteers
- 144 people
- Sponsor
- Pharmanutra S.p.a.
Dental Caries
2-year Caries Clinical Study: Arginine Fluoride-Free Toothpastes vs. NaF Toothpaste
The objective of this study is to evaluate the anticaries efficacy for three dentifrices (1.5% arginine in a calcium base, 8.0% arginine in a calcium base, and 0.32% sodium fluoride in a silica base) in a two-year caries clinical…
- Trial name
- NCT05560945
- Testing
- 0.32% Sodium Fluoride Dentifrice Toothpaste, 1.5% Arginine Dentifrice, 8.0% Arginine Dentifrice
- Where
- 3 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Soft Tissue Sarcoma
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
- Trial name
- NCT05712694
- Testing
- ADI PEG20
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 218 people
- Sponsor
- Polaris Group
Hepatocellular Carcinoma
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
Assessment of safety and tolerability of ADI-PEG 20 in combination with sorafenib in advanced Hepatocellular Carcinoma (HCC).
- Trial name
- NCT02101593
- Testing
- ADI-PEG 20
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Polaris Group
Intellectual Disability, Developmental Delay
Biomarker for Creatine Deficiency Syndromes (BioCDS)
Development of a new mass spectrometry-based biomarker for the ear-ly and sensitive diagnosis of the Creatine Deficiency Syndromes from dry-blood-spot sample
- Conditions
- Intellectual Disability, Developmental Delay, Movement Disorder, Behavioral Disorder
- Trial name
- BioCDS (NCT02934854)
- Where
- 4 sites in Egypt, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Hypersensitivity
Oothpaste Containing 8% Arginine Compared to Colgate Cavity Protection Toothpaste in Reducing Dentinal Hypersensitivity
The objective of this study is to assess clinical efficacy of a toothpaste containing 8% arginine (Colgate-Palmolive Company, New York, NY, USA) to provide dental hypersensitivity relief (tactile and air blast) in comparison to…
- Trial name
- NCT07257042
- Testing
- Toothpaste containing 8% Arginine, Colgate Cavity Protection Toothpaste
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Plaque, Dental
Arginine Plaque Metabolism Pilot Clinical Study
Proof of concept clinical study to measure plaque metabolism and the prebiotic efficacy of arginine-containing toothpaste.
- Trial name
- NCT06954779
- Testing
- Colgate Cavity Protection, TOM's Superior Sensitivity Relief Toothpaste
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Lymphoma, Non-Hodgkin Lymphoma
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in…
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
- Trial name
- PRIMAVERA (NCT06137144)
- Testing
- AZD3470, Pembrolizumab
- Where
- 38 sites in United States, Australia and 9 more
- Volunteers
- 161 people
- Sponsor
- AstraZeneca
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS).
- Trial name
- NCT04278768
- Testing
- Emavusertib, Venetoclax
- Where
- 32 sites in United States, Czechia and 6 more
- Volunteers
- 366 people
- Sponsor
- Curis, Inc.
Dental Caries
A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children
The objective of this study is to assess the safety and to evaluate the anti-caries efficacy of COL101 (arginine) non-fluoride dentifrices compared to a 0.24% sodium fluoride dentifrice in 10-14 year-old children over a one year…
- Trial name
- NCT04750902
- Testing
- 0.24% Sodium Fluoride Dentifrice, 1.5% Arginine Dentifrice, 4.0% Arginine Dentifrice
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 2,025 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Advanced Solid Tumors, Cancer
A Clinical Study of PA5 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if PA5 is safe and works to treat advanced solid tumors in adults. It will also learn about the tolerability and PK/PD profile of PA5.
- Trial name
- NCT07702162
- Testing
- PA5
- Where
- 2 sites in China
- Volunteers
- 49 people
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Dental Caries
To Determine the Ability of a New Product Formulation to Remineralize an Early Caries Lesion by an In-situ Study
This is a double blind, cross-over, controlled clinical trial utilizing thirty (30) adults to evaluate remineralization of early caries lesions.
- Trial name
- NCT02388178
- Testing
- Control toothpaste containing no anti-cavity ingredients, Experimental toothpaste containing fluoride and amino acid (arginine), Fluoride toothpaste containing fluoride as the anti-cavity ingredient
- Volunteers
- healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard…
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
- Trial name
- NCT04603001
- Testing
- LY3410738, Venetoclax, Azacitidine
- Where
- 37 sites in United States, Australia and 10 more
- Volunteers
- 260 people
- Sponsor
- Eli Lilly and Company